Ozmosi | TPX-100 Drug Profile
Drug Search Results
Using advanced filters...
Advanced Search [+]

TPX-100

Alternative Names: tpx-100, tpx100, tpx 100
Clinical Status: Active
Latest Update: 2025-05-12
Latest Update Note: News Article

Product Description

TPX-100 is a candidate first-in-class disease modifying osteoarthritis drug(DMOAD).

Mechanisms of Action: ITG Binder

Novel Mechanism: Yes

Modality: Peptide/Protein

Route of Administration: Subcutaneous

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: OrthoTrophix
Company Location: Western America
Company CEO:
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for TPX-100

Countries in Clinic: United States

Active Clinical Trial Count: 1

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Osteoarthritis, Knee

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

NCT06865079

TPX-100-6

P2

Recruiting

Osteoarthritis, Knee

2027-05-25

50%

2025-05-07

Primary Endpoints|Start Date|Treatments|Trial Status